Until today, there has been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient.
Up to 50% of first line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance, causing a measurable burden on clinic resources and immeasurable patient suffering.
With the IVD CE validated IndiTreat® Sensitivity Test, clinicians can test cancer treatments on patient derived microtumors in order to: